Clinicopathological and molecular significance of Sumolyation marker (ubiquitin conjugating enzyme 9 (UBC9)) expression in breast cancer of black women

Pathology Research and Practice

Volumn 210, Issue 1, 2014, Pages 10-17

  Agboola, A O J ^a,b   Musa, A A ^b   Ayoade, B A ^b   Banjo, A A ^b   Anunobi, C C ^b   Deji Agboola, A M ^b   Rakha, E A ^a   Nolan, C ^a   Ellis, I O ^a   Green, A R ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b OLABISI ONABANJO UNIVERSITY   (Nigeria)

Author keywords

Black women; Breast cancer; Patient outcome; UBC9

Indexed keywords

BRCA1 PROTEIN; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; METASTASIS TUMOR ANTIGEN 1; P CADHERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE; PROTEIN MDMX; PROTEIN P21; PROTEIN P27; PROTEIN P53; TUMOR ANTIGEN; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME 9; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; NIGERIA; OUTCOME ASSESSMENT; PHENOTYPE; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER;

BLACK WOMEN; BREAST CANCER; PATIENT OUTCOME; UBC9;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NIGERIA; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84891482126     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2013.09.011     Document Type: Article

References (44)

1. Morris G.J., Naidu S., Topham A.K., Guiles F., Xu Y., McCue P., Schwartz G.F., Park P.K., Rosenberg A.L., Brill K., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007, 110(4):876-884.
2. Turner N.C., Reis-Filho J.S. Basal-like breast cancer and the BRCA1 phenotype. Oncogene 2006, 25(43):5846-5853.
3. Qin Y., Xu J., Aysola K., Begum N., Reddy V., Chai Y., Grizzle W.E., Partridge E.E., Reddy E.S., Rao V.N. Ubc9 mediates nuclear localization and growth suppression of BRCA1 and BRCA1a proteins. Journal of Cellular Physiology 2011, 226(12):3355-3367.
4. Roth W., Sustmann C., Kieslinger M., Gilmozzi A., Irmer D., Kremmer E., Turck C., Grosschedl R. PIASy-deficient mice display modest defects in IFN and Wnt signaling. Journal of Immunology 2004, 173(10):6189-6199.
5. Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F., Grosschedl R: PIASy a nuclear matrix-associated SUMO E3 ligase, represses LEF1 activity by sequestration into nuclear bodies. Genes & Development 2001, 15(23):3088-3103.
6. Kawai-Kowase K., Kumar M.S., Hoofnagle M.H., Yoshida T., Owens G.K. PIAS1 activates the expression of smooth muscle cell differentiation marker genes by interacting with serum response factor and class I basic helix-loop-helix proteins. Molecular and Cellular Biology 2005, 25(18):8009-8023.
7. Peng Y., Lee J., Zhu C., Sun Z. A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription. The Journal of Biological Chemistry 2010, 285(15):11465-11475.
8. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Molecular Endocrinology 2005, 19(11):2671-2684.
9. Lee J., Beliakoff J., Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Research 2007, 35(13):4523-4534.
10. Miyauchi Y., Yogosawa S., Honda R., Nishida T., Yasuda H. Sumoylation of Mdm2 by protein inhibitor of activated STAT (PIAS) and RanBP2 enzymes. The Journal of Biological Chemistry 2002, 277(51):50131-50136.
11. Morris J.R., Boutell C., Keppler M., Densham R., Weekes D., Alamshah A., Butler L., Galanty Y., Pangon L., Kiuchi T., et al. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress. Nature 2009, 462(7275):886-890.
12. Wei J., Costa C., Ding Y., Zou Z., Yu L., Sanchez J.J., Qian X., Chen H., Gimenez-Capitan A., Meng F., et al. mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer. Journal of the National Cancer Institute 2011, 103(20):1552-1556.
13. Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R. SUMOylation SUMO-interacting motif (SIM) of metastasis tumor antigen 1 (MTA1) synergistically regulate its transcriptional repressor function. The Journal of biological chemistry 2011, 286(51):43793-43808.
14. Baek S.H. A novel link between SUMO modification and cancer metastasis. Cell Cycle 2006, 5(14):1492-1495.
15. Zhu S., Sachdeva M., Wu F., Lu Z., Mo Y.Y. Ubc9 promotes breast cell invasion and metastasis in a sumoylation-independent manner. Oncogene 2010, 29(12):1763-1772.
16. Kurtzman A.L., Schechter N. Ubc9 interacts with a nuclear localization signal and mediates nuclear localization of the paired-like homeobox protein Vsx-1 independent of SUMO-1 modification. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(10):5602-5607.
17. Kaul S., Blackford J.A., Cho S., Simons S.S. Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors. The Journal of Biological Chemistry 2002, 277(15):12541-12549.
18. Mo Y.Y., Yu Y., Theodosiou E., Ee P.L., Beck W.T. A role for Ubc9 in tumorigenesis. Oncogene 2005, 24(16):2677-2683.
19. McDoniels-Silvers A.L., Nimri C.F., Stoner G.D., Lubet R.A., You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2002, 8(4):1127-1138.
20. Dunnebier T., Bermejo J.L., Haas S., Fischer H.P., Pierl C.B., Justenhoven C., Brauch H., Baisch C., Gilbert M., Harth V. et al: Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. International Journal of Cancer 2009, 125(3):596-602.
21. Wu F., Zhu S., Ding Y., Beck W.T., Mo Y.Y. MicroRNA-mediated regulation of Ubc9 expression in cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15(5):1550-1557.
22. Moschos S.J., Smith A.P., Mandic M., Athanassiou C., Watson-Hurst K., Jukic D.M., Edington H.D., Kirkwood J.M., Becker D: S.A.G.E. antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas. Oncogene 2007, 26(29):4216-4225.
23. Kobayashi S., Shibata H., Yokota K., Suda N., Murai A., Kurihara I., Saito I., Saruta T. FHL2, UBC9, and PIAS1 are novel estrogen receptor alpha-interacting proteins. Endocrine Research 2004, 30(4):617-621.
24. Xu J., Watkins T., Reddy A., Reddy E.S., Rao V.N. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. International Journal of Oncology 2009, 34(4):939-949.
25. Moschos S.J., Jukic D.M., Athanassiou C., Bhargava R., Dacic S., Wang X., Kuan S.F., Fayewicz S.L., Galambos C., Acquafondata M., et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Human Pathology 2010, 41(9):1286-1298.
26. Chen S.F., Gong C., Luo M., Yao H.R., Zeng Y.J., Su F.X. Ubc9 expression predicts chemoresistance in breast cancer. Chinese Journal of Cancer 2011, 30(9):638-644.
27. Agboola A.O., Banjo A.A., Anunobi C.C., Salami B., Agboola M.D., Musa A.A., Nolan C.C., Rakha E.A., Ellis I.O., Green A.R. Cell proliferation (KI-67) Expression is associated with poorer prognosis in Nigerian compared to British breast cancer women. ISRN Oncology 2013, 2013:675051.
28. Agboola A.J., Musa A.A., Wanangwa N., Abdel-Fatah T., Nolan C.C., Ayoade B.A., Oyebadejo T.Y., Banjo A.A., Deji-Agboola A.M., Rakha E.A., et al. Molecular characteristics and prognostic features of breast cancer in Nigerian compared with UK women. Breast Cancer Research and Treatment 2012, 135(2):555-569.
29. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., et al. American society of clinical oncology/college of american pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology 2007, 25(1):118-145.
30. Garcia-Caballero T., Grabau D., Green A.R., Gregory J., Schad A., Kohlwes E., Ellis I.O., Watts S., Mollerup J. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens. Histopathology 2010, 56(4):472-480.
31. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z., Hernandez-Boussard T., Livasy C., Cowan D., Dressler L., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2004, 10(16):5367-5374.
32. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. Reporting recommendations for tumor marker prognostic studies. Journal of Clinical Oncology 2005, 23(36):9067-9072.
33. Brayman M.J., Dharmaraj N., Lagow E., Carson D.D. MUC1 expression is repressed by protein inhibitor of activated signal transducer and activator of transcription-y. Molecular Endocrinology 2007, 21(11):2725-2737.
34. Coppola D., Parikh V., Boulware D., Blanck G. Substantially reduced expression of PIAS1 is associated with colon cancer development. Journal of Cancer Research and Clinical Oncology 2009, 135(9):1287-1291.
35. Fanelli M.A., Montt-Guevara M., Diblasi A.M., Gago F.E., Tello O., Cuello-Carrion F.D., Callegari E., Bausero M.A., Ciocca D.R. P-cadherin beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress & Chaperones 2008, 13(2):207-220.
36. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., Cano A., Moreno-Bueno G., Palacios J. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Research 2008, 68(4):989-997.
37. Zuo L., Li W., You S. Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway. Breast Cancer Research: BCR 2010, 12(3):R34.
38. Bergamaschi A., Kim Y.H., Kwei K.A., La Choi Y., Bocanegra M., Langerod A., Han W., Noh D.Y., Huntsman D.G., Jeffrey S.S., et al. CAMK1D amplification implicated in epithelial-mesenchymal transition in basal-like breast cancer. Molecular Oncology 2008, 2(4):327-339.
39. Lamouille S., Derynck R. Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. The Journal of Cell Biology 2007, 178(3):437-451.
40. Yeh Y.Y., Chiao C.C., Kuo W.Y., Hsiao Y.C., Chen Y.J., Wei Y.Y., Lai T.H., Fong Y.C., Tang C.H. TGF-beta1 increases motility and alphavbeta3 integrin up-regulation via PI3K, Akt and NF-kappaB-dependent pathway in human chondrosarcoma cells. Biochemical Pharmacology 2008, 75(6):1292-1301.
41. Wang C., Liu X., Ke Z., Tang Y., Li C.C., Li C.M., Ye Z., Zhang J., Lou T. Mesangial Medium from IgA Nephropathy Patients Induces Podocyte Epithelial-to-mesenchymal Transition through Activation of the Phosphatidyl Inositol-3-kinase/Akt Signaling Pathway. Cellular Physiology and Biochemistry: International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology 2012, 29(5-6):743-752.
42. Abdel-Fatah T.M., Powe D.G., Agboola J., Adamowicz-Brice M., Blamey R.W., Lopez-Garcia M.A., Green A.R., Reis-Filho J.S., Ellis I.O. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. The Journal of Pathology 2010, 220(4):419-434.
43. Kahyo T., Nishida T., Yasuda H. Involvement of PIAS1 in the sumoylation of tumor suppressor p53. Molecular Cell 2001, 8(3):713-718.
44. Park M.A., Seok Y.J., Jeong G., Lee J.S. SUMO1 negatively regulates BRCA1-mediated transcription, via modulation of promoter occupancy. Nucleic Acids Research 2008, 36(1):263-283.